Helpful Insights forPatients and Caregivers

Antipsychotic Induced Weight Gain

Download PDF

Antipsychotics are used to treat several mental health conditions including schizophrenia, bipolar disorder, and psychosis. These medications can have less side effects but can lead to weight gain.

References

  1. DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021;11(6):311-319. Published 2021 Nov 8. doi:10.9740/mhc.2021.11.311
  2. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-2241. Published 2017 Aug 22. doi:10.2147/NDT.S113099
  3. Fitzgerald I, O'Connell J, Keating D, Hynes C, McWilliams S, Crowley EK. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022;25(1):15-22. doi:10.1136/ebmental-2021-300291
  4. McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008
  5. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596
  6. Metformin. Package insert. Bristol-Myers Squibb; 2000.
  7. Topiramate. Package insert. Janssen Pharmaceuticals, Inc.; 2017.
  8. Semaglutide. Package insert. Novo Nordisk Inc.; 2019.
  9. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. doi:10.1016/S0140-6736(23)01185-6
  10. Liraglutide. Package insert. Novo Nordisk Inc.; 2018.